GastroPanel®

GastroPanel is a patient-friendly blood test for assessing the structure and function of the stomach in patients with Dyspepsia. It is a simple and painless means to find out whether an individual has a healthy or atrophied stomach mucosa.

In primary care stomach problems present as pain or discomfort, heartburn, a feeling of heaviness, bloating, nausea or vomiting. And sometimes, even severe conditions that require medical attention, can be asymptomatic.

GastroPanel is a blood test that GPs use to support the diagnosis and referral of patients with stomach symptoms It is suitable for all adults suffering from gastric complaints and diagnoses Atrophic Gastritis as well as Helicobacter pylori.

Left untreated, Helicobacter pylori and atrophic gastritis can progress to gastric cancer through a sequence of mucosal changes (Correa's Cascade). It is therefore important to exclude atrophic gastritis early as part of routine investigations for dyspepsia.

What does GastroPanel detect?

 

GastroPanel® is intended as the first-line diagnostic test for dyspeptic complaints to detect Helicobacter pylori infection and atrophic gastritis (mucosal atrophy) caused by Helicobacter pylori or autoimmune disease.

 

The GastroPanel test also informs the the doctor about risks associated with atrophic gastritis (e.g. gastric and oesophageal cancer) as well as malabsorption of vitamin B12, calcium, magnesium, zinc, iron and certain medicines.

GastroPanel reveals the stomach's capacity for producing acid so when it comes to prescribing antacids such as PPIs and H2RAs the physician can evaluate the need for such drugs. For example, GastroPanel identifies corpus atrophic gastritis, a condition that impedes gastric acid production in the stomach. Therefore antacid therapy in such individuals is contraindicated.

Select and prioritise Gastroscopy

Diagnose high risk conditions

Confirm need for PPI therapy

For GP and Specialist use

Diagnose Dyspepsia with GastroPanel™

When patients present with dyspepsia and stomach complaints use GastroPanel as a first line test to diagnose Helicobacter pylori and atrophic gastritis prior to prescribing PPIs or referral for gastroscopy.

GastroPanel is a simple, effective and low cost test that reveals the health and status of the gastric mucosa and informs them about the risks associated with the findings. This enables doctors to formulate appropriate and effective treatment plans for their patients including eradication therapy, referral for further investigation, or prescribing advice for antacids.

Ways to test your patients using GastroPanel

Unifiedkits 500x288.png

GastroPanel™

Kit for Labs

Set up GastroPanel in your own laboratory with ease

BiohitHealthcare_logo_CMYK_10x5cm.jpg

GastroPanel™ Service Laboratory

Send samples to our service laboratory for GastroPanel analysis

Frequently asked Questions

What is atrophic Gastritis and why is it important to test for it?

Gastritis is a common term that is used to describe inflammation of the gastric mucosa. In Atrophic Gastritis chronic inflammation leads to the progressive loss of gastric glandular cells in the mucosa, which in turn impairs the output of acid. Loss of cells is closely reflected by the biomarker concentrations of the GastroPanel® test. Decreased (lost) secretion of gastric acid and intrinsic factor (IF) from the gastric mucosa is a risk factor for Vitamin B12- and micronutrient deficiency.

 

Atrophic gastritis can be caused by Helicobacter pylori infection and autoimmune disease. It is important to test for Atrophic gastritis due to the significant increase in risk of gastric cancer in individuals who have the disease.

Atrophic Gastritis is the greatest independent risk factor for Gastric Cancer known. According to expert opinion atrophic gastritis is present in 10% of individuals affected by chronic H. pylori infection. It is easy to test for both H. pylori and Atrophic Gastritis using GastroPanel.

Diagnosing Atrophic Gastritis in Primary Care has implications for the management of patients with dyspepsia too. Individuals who suffer from Corpus Atrophic Gastritis have impaired gastric function and are often achlorhydric or hypochlorhydric. In such patients antacid use for the treatment of dyspepsia may be contraindicated.

Autoimmune Atrophic Gastritis is also associated with Type I gastric neuroendocrine tumours, which although rare, these lesions are being identified at endoscopy more and more frequently.

Is GastroPanel for GPs (Primary Care) or Specialists (Secondary Care)?

Both, but for different indications.

 

In Primary Care GastroPanel is used as a first line test in the diagnosis of dyspepsia. Replace standalone H. pylori tests with GastroPanel and test before administering antacids to gain a better understanding of how to manage the patient. GastroPanel helps select patients who need endoscopy and identifies those patients in whom antacids are contraindicated.

In Secondary Care GastroPanel is used to monitor disease progression/regression in patients with atrophic gastritis. It can also be used to predict the course of disease from the long-term follow up clinical trials that have been published. GastroPanel can also be used to help identify patients with atrophic gastritis in conjunction with gastroscopy, where the disease is often difficult to identify visually. GastroPanel can therefore help direct targeted biopsy analysis or save on histopathology resources.

What does GastroPanel measure in blood?

GastroPanel detects and quantifies four plasma biomarkers:

It measures the four analytes using highly specific ELISAs that produce individual assay results. These results are then fed into a sophisticated algorithm to reduce the data and produce a report for the physician.

More information about the individual analytes is available in the product pages. Just click the links above.

What information is included in my report?

The GastroPanel report delivers patient-specific information relating to their condition. The four biomarkers measured (Pepsinogen I, Pepsinogen II, Gastrin 17 and Helicobacter pylori IgG) are reported individually and numerically against the reference ranges for the individual assays. The report also shows the interpretation of results following the data reduction by GastroSoft - BIOHITs proprietary algorithm for GastroPanel.

Each report includes a written description of the test results along with recommendations for further investigations. You can try the GastroSoft data reduction software and generate your own sample report here.

How does GastroPanel fit into current guidance and guidelines?

GastroPanel builds on existing guidance for the diagnosis of dyspepsia. By replacing your stand alone Helicobacter pylori test with GastroPanel you gain from being able to obtain information about the health and functionality of the stomach as well as the H. pylori status. Helicobacter pylori tests alone lack important information that can only be revealed by GastroPanel, specifically in relation to the presence or absence of pre-neoplastic conditions such as atrophic gastritis and the related risks. But also, atrophic gastritis is not exclusively caused by H. pylori - autoimmune atrophic gastritis is not detectable by H. pylori tests.

Guidelines often lead to widespread PPI use, which, whilst effective for a large proportion of individuals, are not indicated for individuals who suffer from atrophic gastritis who do not produce, or have impaired secretion of gastric acid.

Therefore GastroPanel fits well with existing guidelines and can be adopted as an advanced Helicobacter pylori test in order to enhance the existing patient pathway, and to help identify those individuals who are h. pylori negative but suffer from autoimmune atrophic gastritis.

How accurate is GastroPanel?

GastroPanel has been validated in many clinical studies worldwide. In a recent systematic review with meta-analysis on the diagnostic accuracy of GastroPanel for atrophic gastritis[1], the following performance characteristics were reported:

Sensitivity = 74.7% (95% CI, 62.0-84.3)

Specificity = 95.6% (95%CI, 92.6-97.4).

 

With a median prevalence of atrophic gastritis of 27% the Negative Predictive Value = 91%

1. Aliment Pharmacol Ther. 2017;46:657–667

BIOHIT HealthCare in Reflux and Dyspepsia 

Millions of people in the UK and worldwide suffer from non-specific gastroesophageal symptoms which are challenging for the treating physician to manage. BIOHIT HealthCare has academic interest in dyspepsia as well as a commercial role in supplying innovative test systems to help physicians diagnose and monitor dyspepsia and associated diseases.

 

BIOHIT HealthCare supplies essential tests that help investigate dyspepsia in Primary and Secondary Care, helping treating physicians to adopt a test-and -treat or test-and-refer strategy to improve their practice. With BIOHIT's non-invasive GastroPanel and Peptest diagnostic tests, the treating physician can determine the health and function of the stomach prior to treating, and, gain a clear understanding of the involvement of acid and pepsin. The tests help physicians decide whether the patient should be referred to Secondary Care for further investigation or treated in Primary Care with confidence.